Communiqués Cogent Biosciences, Inc.

Actions

COGT

US19240Q2012

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 30/07/2026			Varia. 5j.	Varia. 1 janv.
41,36 ^USD	+4,52%		+2,78%	+16,44%

30/06	Cogent Biosciences dépose une demande d'autorisation de mise sur le marché pour le bezuclastinib dans la mastocytose systémique avancée	CI
30/06	Cogent Biosciences dépose une demande d'autorisation de mise sur le marché auprès de la FDA pour un traitement contre la mastocytose	MT

Communiqués

30/06	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)	AQ
12/06	Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress	AQ
12/06	Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress	AQ
30/05	Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
28/05	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST	AQ
27/05	Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference	AQ
12/05	Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress	AQ
05/05	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results	AQ
21/04	Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
17/04	Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026	AQ
01/04	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)	AQ
16/03	Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)	AQ
02/03	Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting	AQ
28/02	Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting	AQ
17/02	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results	AQ
10/02	Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting	AQ
26/01	Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)	AQ
20/01	Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)	AQ
13/01	Cogent Biosciences : COGT JPM 26 FINAL	PU
12/01	Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio	AQ
06/01	Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
30/12	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis	AQ
08/12	Cogent Biosciences : COGT ASH 2025 Webcast FINAL	PU
08/12	Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)	AQ
06/12	Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)	AQ